China drug prices were cut more than expected, Credit Suisse says

Bloomberg

10 December 2018 - Serena Shao, head of China healthcare research at Credit Suisse, talks about Chin's health care stocks. 

The country's drug stocks continue slide, extending losses to 16% over the past four trading days, after the government confirmed prices in a centralised tender fell by an average 52% from a year earlier.

Read Bloomberg article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Regulation , Pricing , China